Results 181 to 190 of about 3,258,233 (341)

Radiation‐Resistant Bacteria Deinococcus radiodurans‐Derived Extracellular Vesicles as Potential Radioprotectors

open access: yesAdvanced Healthcare Materials, EarlyView.
Deinococcus radiodurans‐derived extracellular vesicles (R1‐EVs) provide radioprotection against total‐body irradiation‐induced acute radiation syndrome in mice. R1‐EVs mitigate oxidative damage by scavenging free radicals, promoting intestinal repair, enhancing hematopoietic function, and modulating immune responses. This study highlights the potential
Jeong Moo Han   +7 more
wiley   +1 more source

Novel Less Toxic, Lymphoid Tissue‐Targeted Lipid Nanoparticles Containing a Vitamin B5‐Derived Ionizable Lipid for mRNA Vaccine Delivery

open access: yesAdvanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
The top‐performing lipid nanoparticle, incorporating a novel ionizable lipid derived from vitamin B5, demonstrates high mRNA transfection efficiency, low toxicity, favorable stability, targeted delivery to lymphoid tissues, and high immunogenicity, showing promise as a carrier for mRNA vaccines for infectious diseases and cancer.
Soyeon Yoo   +11 more
wiley   +1 more source

Bioengineering a Patient‐Derived Vascularized Lung Tumor‐on‐Chip Model to Decipher Immunomodulation by the Endothelium

open access: yesAdvanced Healthcare Materials, EarlyView.
Most in vitro cancer models lack cellular diversity, functional complexity, and clinical relevance. This work highlights the generation of an innovative dynamic tetraculture with autologous patient‐derived cells within a vascularized tumor‐on‐chip, as well as the recapitulation of endothelial anergy features induced by the tumor microenvironment ...
Christine Lansche   +16 more
wiley   +1 more source

Glepaglutide‐Loaded Foam for the Induction of Mucosal Healing in the Treatment of Inflammatory Bowel Disease

open access: yesAdvanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
Glepaglutide (GL), a GLP‐2 analog with an extended half‐life (50 h), is currently undergoing clinical trials for patients with short bowel syndrome. GL requires subcutaneous injection, which poses challenges for potential patient compliance. To address this challenge, we loaded GL into a rectal foam formulation using CO2 as a permeation enhancer to ...
Wunan Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy